Compare Walt Disney Co (DIS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walt Disney Co vs Summit Therapeutics Inc — how do they compare? Walt Disney Co trades at $108.05 (market cap $184.79B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Walt Disney Co is far larger — about 13.5× Summit Therapeutics Inc's market cap, and Walt Disney Co pays a 1.4% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and Summit Therapeutics Inc for 16 Days on average.
| DIS | SMMT | |
|---|---|---|
Market Cap | $184.79B | $13.71B |
Volume | 13,033,550 | 6,173,057 |
Sector | Media | Health |
52-Week High | $116.65 | $26.38 |
52-Week Low | $92.40 | $12.43 |
Typical Hold Time | 199 Days | 16 Days |
Enterprise Value | $225.65B | $13.04B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $107.08, up 2.21% today, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. Revenue grew to $94.43B in 2025, with net income surging to $12.40B, though free cash flow faces pressure from increased investments. The stock remains below the analyst consensus price target of $125.67, indicating potential upside.
The outlook is positive with strong fundamentals and analyst support, but risks include streaming competition and high capital expenditures. Investment opportunity lies in execution of the $60B parks pipeline and streaming margin expansion, balanced against macroeconomic sensitivity and execution risks.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walt Disney Co
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
